Posted by TriedEveryMedication on July 29, 2022, at 22:17:11
I've been following clinical trials of depression meds in development for 10-15 years. Most crash and burn, even the promising ones. (Remember NSI-189?). Here are the recent trials I've dug up
- Ansofaxine/LY03005, a prodrug to desvenlafaxine being tried in china
Not sure why there would be a benefit to using a prodrug, maybe to increase the effective half-life of desvenlafaxine? Or maybe just a new revenue source.
https://en.wikipedia.org/wiki/Ansofaxine
Phase 2 trial results. The p-value of 4.5% is borderline questionable https://pubmed.ncbi.nlm.nih.gov/34747448/- AXS-05 / dextromethorphan-bupropion
NMDA antagonist. I guess the idea with this is the bupropion inhibits some of the metabolism of the DXM. My p-doc is actually doing a DIY version of this with some patients. I tried it and it just made me feel weird. phase 2 results:
https://ajp.psychiatryonline.org/doi/10.1176/appi.ajp.21080800- MIJ821
A NMDA subtype negative allosteric modulator. Currently in phase 2 until 2024
- Nitrous Oxide
Another NMDA antagonist. In phase 2 until 2023.
- Psilocybin & DMT
Various trials, not sure how close either of these are to approval. Interestingly in Oakland, CA Psilocybin has been decriminalized and according to my p-doc there are therapists doing not-so-underground therapy sessions with psychedelics there.
- Recent failures
ALKS-5461 / Buprenorphine/samidorphan - opioid receptor MOA. Despite a really strong phase 2 showing, it failed in phase 3, lack of efficacy
rapastinel - NMDA antagonist - failed in phase 3
poster:TriedEveryMedication
thread:1120171
URL: http://www.dr-bob.org/babble/20220530/msgs/1120171.html